The raised guidance and 14% Royalty Receipts growth confirm strong underlying portfolio momentum. Watch for upcoming PDUFA dates (daraxonrasib NDA acceptance, deucrictibant April 2027) and further transaction announcements as the company deploys capital into new royalties.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $57.75entry
- T+1 · 3mo ago −0.85%α −0.69% · $57.26
- T+5 · 3mo ago +2.55%α +2.19% · $59.22
- T+20 · 3mo ago +9.28%α +9.88% · $63.11
- T+60 · 19d ago +12.99%α +12.79% · $65.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $773M (+6% YoY) and Portfolio Cash Flow per diluted share of $1.32, beating the $1.27 consensus by 3.9%. The company raised its full-year 2026 Portfolio Receipts guidance to $3,400-$3,500 million from $3,325-$3,450 million, driven by strong 14% Royalty Receipts growth from Tremfya, Voranigo, Imdelltra, and Evrysdi.
Key Financial Metrics
Key Facts
- Portfolio Receipts of $773M in Q2 2026, up 6% YoY from $727M
- Royalty Receipts of $768M, up 14% YoY from $672M
- Portfolio Cash Flow of $736M, up 15% YoY from $641M
- EPS (Portfolio Cash Flow per share) of $1.32 vs consensus $1.27 (beat by 3.9%)
- Raised full-year 2026 Portfolio Receipts guidance to $3,400-$3,500M from $3,325-$3,450M
- Capital Deployment of $1.1B YTD; acquired royalty on AstraZeneca's cliramitug for up to $425M
- Repurchased 0.9M shares for $45M in Q2; quarterly dividend of $0.235 per share
- Net cash provided by operating activities of $728M, up 100% YoY
Financial Impact
EPS beat of ~$0.05 vs consensus; guidance midpoint raised by ~$75M; Portfolio Receipts grew 6% YoY
Risk Factors
- Concentration in cystic fibrosis franchise ($194M, ~25% of Portfolio Receipts) from Vertex
- Declining Promacta revenue due to U.S. generic competition
- High debt of $9.2B exposes to rising interest rate environment
- Milestones and other contractual receipts volatile ($5M vs $56M YoY)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001802768-26-000014 |
| Document: 0001802768-26-000014-index.html | 0001802768-26-000014 |
| Document: 0001802768-26-000014.txt | 0001802768-26-000014 |
| 8-K Data (Synthetic) | 0001802768-26-000014 |
Track record
23 reports on RPRX
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $69.31 +2.58% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $69.31 +2.59% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $69.31 −20.27% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $69.31 −14.39% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $69.31 +14.44% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $69.31 +18.36% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Viewing Entry $57.75 to $59.22 Now $69.31 +20.02% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $69.31 +19.98% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers